~80 years of life maybe (seems optimistic for these regions) but surely not ~80 DALYs in expectancy for under 5s? What about morbidity that can be expected to be had by the kids you save? Does this come into the discounting decision?
Also, Hauke, do you have an idea, personally, of the additional benefit (as a number) in terms of HIV / adult suffering / disease dynamics / reduction of health income shocks etc. etc. from reducing the incidence of malaria beyond avoiding child deaths that you helpfully walk people through in your GWWC article on malaria?
~80 years of life maybe (seems optimistic for these regions) but surely not ~80 DALYs in expectancy for under 5s? What about morbidity that can be expected to be had by the kids you save? Does this come into the discounting decision?
In the DALY framework, people never take into account the regional life expectancy, but a more general or sometimes even western standard life expectancy (Average worldwide life expectancy is 70 years). I think this might be justified as life expectancy is increasing world wide and because of that could even be an underestimate.
Also, Hauke, do you have an idea, personally, of the additional benefit (as a number) in terms of HIV / adult suffering / disease dynamics / reduction of health income shocks etc. etc. from reducing the incidence of malaria beyond avoiding child deaths that you helpfully walk people through in your GWWC article on malaria?
These coinfections are complex issues and all estimates are very uncertain. I review the literature around this here:
The main point here is that, Malaria interventions are already very cost-effective even when just taking into account childhood mortality, and independent of the effect size of these interactions, you might avert some HIV infections on top the more established effects ‘for free’.
~80 years of life maybe (seems optimistic for these regions) but surely not ~80 DALYs in expectancy for under 5s? What about morbidity that can be expected to be had by the kids you save? Does this come into the discounting decision?
Also, Hauke, do you have an idea, personally, of the additional benefit (as a number) in terms of HIV / adult suffering / disease dynamics / reduction of health income shocks etc. etc. from reducing the incidence of malaria beyond avoiding child deaths that you helpfully walk people through in your GWWC article on malaria?
In the DALY framework, people never take into account the regional life expectancy, but a more general or sometimes even western standard life expectancy (Average worldwide life expectancy is 70 years). I think this might be justified as life expectancy is increasing world wide and because of that could even be an underestimate.
These coinfections are complex issues and all estimates are very uncertain. I review the literature around this here:
https://www.givingwhatwecan.org/blog/2015-04-24/update-against-malaria-foundation
The main point here is that, Malaria interventions are already very cost-effective even when just taking into account childhood mortality, and independent of the effect size of these interactions, you might avert some HIV infections on top the more established effects ‘for free’.